Screener
ADMA Biologics ADMA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
FAQ
- What is ADMA Biologics's total equity?
- ADMA Biologics (ADMA) reported total equity of $408.21M in Q2 2026.
- How has ADMA Biologics's total equity changed year-over-year?
- ADMA Biologics's total equity increased by 2.5% year-over-year, from $398.33M to $408.21M.
- What is the long-term trend for ADMA Biologics's total equity?
- Over 5 years (2020 to 2025), ADMA Biologics's total equity has grown at a 40.2% compound annual growth rate (CAGR), from $88.25M to $477.32M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about ADMA Biologics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude